Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

-- ARBITRATION TRIBUNAL DECLARED THAT PM647 IS WITHIN PRIME MEDICINE'S FIELD, CONFIRMING PRIME MEDICINE'S RIGHT TO DEVELOP AND COMMERCIALIZE PM647 IN AATD -- -- PRIME MEDICINE OWES NO MONETARY DAMAGES TO BEAM THERAPEUTICS -- -- PRIME MEDICINE PLANS TO SUBMIT AN IND AND/OR CTA FILING FOR PM647 IN Q3 2026, INITIAL CLINICAL DATA EXPECTED IN 2027 -- CAMBRIDGE, MASS., JULY 08, 2026 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED A POSITIVE, BINDING RESOLUTION OF ITS PREVIOUSLY DISCLOSED ARBITRATION WITH BEAM THERAPEUTICS, INC. RELATING TO THE PARTIES' 2019 COLLABORATION AND LICENSE AGREEMENT (AGREEMENT).

PRIME MEDICINE ANNOUNCES POSITIVE RESOLUTION TO ARBITRATION WITH BEAM THERAPEUTICS

-- RMAT DESIGNATION GRANTED BASED ON PHASE 1/2 CLINICAL DATA, INCLUDING RESULTS PREVIOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE, DEMONSTRATING PM359'S POTENTIAL TO ADDRESS UNMET NEED IN P47 PHOX -DEFICIENT CGD -- -- DESIGNATION ENABLES EARLY AND INTENSIVE FDA ENGAGEMENT, AND PROVIDES ELIGIBILITY FOR ROLLING AND PRIORITY BIOLOGICS LICENSE APPLICATION REVIEW -- -- PM359 NOW HOLDS RMAT, FAST TRACK, ORPHAN DRUG, AND RARE PEDIATRIC DISEASE DESIGNATIONS -- CAMBRIDGE, MASS., JUNE 22, 2026 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION TO PM359, AN INVESTIGATIONAL AUTOLOGOUS PRIME EDITED HEMATOPOIETIC STEM CELL THERAPY FOR THE TREATMENT OF P47PHOX-DEFICIENT CHRONIC GRANULOMATOUS DISEASE (CGD).

PRIME MEDICINE RECEIVES U.S. FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR PM359 FOR THE TREATMENT OF CHRONIC GRANULOMATOUS DISEASE (CGD)

-- FIRST CLINICAL AUTHORIZATION FOR AN IN VIVO PRIME EDITING THERAPY FROM PRIME MEDICINE -- -- PM577A TARGETS THE H1069Q MUTATION IN THE ATP7B GENE, THE MOST PREVALENT WD-CAUSING ALLELE IN NORTH AMERICA AND EUROPE --

PRIME MEDICINE ANNOUNCES NEW ZEALAND CLEARANCE OF CLINICAL TRIAL APPLICATION FOR PM577A IN H1069Q-MUTATED WILSON DISEASE

MONTREAL, JUNE 12, 2026 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES THAT IT IS PROCEEDING WITH A NON-BROKERED PRIVATE PLACEMENT OFFERING OF UNITS OF THE COMPANY (THE UNITS) TO RAISE MINIMUM GROSS PROCEEDS OF $1,200,000 AND MAXIMUM GROSS PROCEEDS OF $2,200,000 (THE UNIT OFFERING).

PRIME DRINK GROUP ANNOUNCES PRIVATE PLACEMENT AND AGREED RESOLUTION WITH CREDITORS

CAMBRIDGE, MASS., JUNE 03, 2026 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT ALLAN REINE, M.D.

PRIME MEDICINE TO PRESENT AT GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

CAMBRIDGE, MASS., MAY 28, 2026 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THAT ALLAN REINE, M.D.

PRIME MEDICINE TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

CAMBRIDGE, MASS., MAY 07, 2026 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026 AND PROVIDED A BUSINESS UPDATE.

PRIME MEDICINE REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CAMBRIDGE, MASS., APRIL 16, 2026 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THE APPOINTMENT OF SVETLANA MAKHNI AS CHIEF FINANCIAL OFFICER (CFO).

PRIME MEDICINE APPOINTS SVETLANA MAKHNI AS CHIEF FINANCIAL OFFICER

MONTRAL, APRIL 14, 2026 (GLOBE NEWSWIRE) -- PRIME DRINK GROUP CORP. (CSE: PRME) (PRIME OR THE COMPANY) ANNOUNCES A NON-BROKERED PRIVATE PLACEMENT (THE PRIVATE PLACEMENT) OF A MINIMUM OF 10 UNITS (EACH, A UNIT) AND A MAXIMUM OF 16 UNITS AT A PRICE OF $250,000 PER UNIT, FOR MINIMUM AND MAXIMUM GROSS PROCEEDS OF $2,500,000 AND $4,000,000, RESPECTIVELY.

PRIME DRINK GROUP ANNOUNCES CONVERTIBLE DEBENTURE, BOARD APPOINTMENT AND GRANT OF DIFFERED SHARE UNITS

-- ON TRACK TO FILE IND AND/OR CTA FOR WILSON DISEASE AND AATD PROGRAMS IN 1H 2026 AND MID-2026, RESPECTIVELY; INITIAL CLINICAL DATA FOR BOTH EXPECTED IN 2027 -- -- ONGOING ENGAGEMENT WITH FDA FOR PM359 IN CGD; PLAN TO SUBMIT BLA FOLLOWING FINAL ALIGNMENT -- -- PRIME MEDICINE REPORTED CASH, CASH EQUIVALENTS, INVESTMENTS, AND RESTRICTED CASH OF $191M PROVIDING CASH RUNWAY INTO 2027 -- CAMBRIDGE, MASS., MARCH 03, 2026 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2025 AND PROVIDED A BUSINESS UPDATE.

Prime Medicine, Inc.

PRME

Price

Financial Reports

No items found.

Press Releases

Prime Medicine, Inc.

PRME.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PRME